Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
The American Journal of Tropical Medicine and Hygiene|March 19, 2003
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999Ananda Nisalak, Timothy P Endy, Suchitra Nimmannitya, et al.
Vaccine|June 24, 2015
AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypesCorey P Mallett, Edith Beaulieu, Marie-Hélène Joly, et al.
Vaccines|January 14, 2021
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret ModelWen-Chun Liu, Raffael Nachbagauer, Daniel Stadlbauer, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccineRobert Edelman, Steven S Wasserman, Sacared A Bodison, et al.
Vaccine|August 1, 2019
Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerationsBruce L Innis, Francesco Berlanda Scorza, Jeremy S Blum, et al.
Vaccine|April 30, 2019
Safety of AS03-adjuvanted influenza vaccines: A review of the evidenceCatherine Cohet, Robbert van der Most, Vincent Bauchau, et al.
Vaccine|August 1, 2019
Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacityBruce L Innis, Francesco Berlanda Scorza, Jeremy S Blum, et al.
Clinical and Diagnostic Laboratory Immunology|May 3, 2002
Quantitation of immunoglobulin to hepatitis E virus by enzyme immunoassayBruce L Innis, Jitvimol Seriwatana, Robin A Robinson, et al.
The Pediatric Infectious Disease Journal|June 4, 2005
Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccinePenelope H Dennehy, Rebecca C Brady, Scott A Halperin, et al.
Open Forum Infectious Diseases|January 27, 2022
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of ProtectionJasur Danier, Andrea Callegaro, Jyoti Soni, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
The American Journal of Tropical Medicine and Hygiene|March 19, 2003
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999Ananda Nisalak, Timothy P Endy, Suchitra Nimmannitya, et al.
Vaccine|June 24, 2015
AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypesCorey P Mallett, Edith Beaulieu, Marie-Hélène Joly, et al.
Vaccines|January 14, 2021
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret ModelWen-Chun Liu, Raffael Nachbagauer, Daniel Stadlbauer, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccineRobert Edelman, Steven S Wasserman, Sacared A Bodison, et al.
Vaccine|August 1, 2019
Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerationsBruce L Innis, Francesco Berlanda Scorza, Jeremy S Blum, et al.
Vaccine|April 30, 2019
Safety of AS03-adjuvanted influenza vaccines: A review of the evidenceCatherine Cohet, Robbert van der Most, Vincent Bauchau, et al.
Vaccine|August 1, 2019
Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacityBruce L Innis, Francesco Berlanda Scorza, Jeremy S Blum, et al.
Clinical and Diagnostic Laboratory Immunology|May 3, 2002
Quantitation of immunoglobulin to hepatitis E virus by enzyme immunoassayBruce L Innis, Jitvimol Seriwatana, Robin A Robinson, et al.
The Pediatric Infectious Disease Journal|June 4, 2005
Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccinePenelope H Dennehy, Rebecca C Brady, Scott A Halperin, et al.
Open Forum Infectious Diseases|January 27, 2022
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of ProtectionJasur Danier, Andrea Callegaro, Jyoti Soni, et al.
Pageof 12